{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T13:11:26Z","timestamp":1791465086820,"version":"4.3.4"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T00:00:00Z","timestamp":1772064000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T00:00:00Z","timestamp":1773619200000},"content-version":"vor","delay-in-days":18,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004359","name":"Vetenskapsr\u00e5det","doi-asserted-by":"publisher","award":["2024-05621"],"award-info":[{"award-number":["2024-05621"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006353","name":"Kjell och M\u00e4rta Beijers Stiftelse","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006353","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Wenner-Gren Stiftelserna\/the Wenner-Gren Foundations"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Commun Biol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Phenotypic adaptation, the ability of cells to change phenotype in response to external pressures, has been identified as a driver of drug resistance in cancer. To quantify phenotypic adaptation in BRAFV600E-mutant melanoma, we develop a theoretical model informed by growth-rate data of WM239A-BRAFV600E cells challenged with the BRAF-inhibitor encorafenib. We use an individual-based model (IBM) in which each cell is described by one of multiple discrete and plastic phenotype states that are directly linked to drug-dependent net growth rates and, by extension, drug resistance. To describe how cells transition between phenotype states, we explore a gamut of candidate models common in the mathematical biology literature. Comparing these on their ability to reproduce in vitro growth curves, data-matched simulations suggest that phenotypic adaptation is directed towards states of high net growth rates, enabling the evasion of drug-effects. The model subsequently provides an explanation for when and why intermittent treatments outperform continuous treatments in the studied system, and demonstrates the benefits of not only targeting, but also leveraging, phenotypic adaptation in treatment protocols. Building on the IBM, we present a flexible mathematical methodology based on ordinary differential equations to compare responses to continuous and intermittent treatments through long-term effective net growth rates.<\/jats:p>","DOI":"10.1038\/s42003-026-09760-2","type":"journal-article","created":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T10:25:19Z","timestamp":1772101519000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Growth rate-driven modelling suggests that phenotypic adaptation drives drug resistance in BRAFV600E-mutant melanoma"],"prefix":"10.1038","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1105-8078","authenticated-orcid":false,"given":"Sara","family":"Hamis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8753-1538","authenticated-orcid":false,"given":"Alexander P.","family":"Browning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrianne L.","family":"Jenner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Villa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0146-9164","authenticated-orcid":false,"given":"Philip K.","family":"Maini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tyler","family":"Cassidy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,26]]},"reference":[{"key":"9760_CR1","doi-asserted-by":"publisher","DOI":"10.1038\/s41389-023-00452-8","volume":"12","author":"S Diazzi","year":"2023","unstructured":"Diazzi, S., Tartare-Deckert, S. & Deckert, M. The mechanical phenotypic plasticity of melanoma cell: an emerging driver of therapy cross-resistance. Oncogenesis 12, 7 (2023).","journal-title":"Oncogenesis"},{"key":"9760_CR2","doi-asserted-by":"publisher","first-page":"4178","DOI":"10.1200\/JCO.21.02659","volume":"40","author":"R Dummer","year":"2022","unstructured":"Dummer, R. et al. COLUMBUS 5-Year Update: a randomized, open-label, phase III trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAFV600E-mutant melanoma. J. Clin. Oncol. 40, 4178\u20134188 (2022).","journal-title":"J. Clin. Oncol."},{"key":"9760_CR3","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1111\/1346-8138.15969","volume":"48","author":"H Fukushima","year":"2021","unstructured":"Fukushima, H., Iwata, Y., Saito, K. & Sugiura, K. Successful rechallenge therapy for braf\/mek inhibitor-resistant multiple brain metastases of melanoma. J. Dermatol 48, 1291\u20131295 (2021).","journal-title":"J. Dermatol"},{"key":"9760_CR4","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/nrclinonc.2017.166","volume":"15","author":"I Dagogo-Jack","year":"2018","unstructured":"Dagogo-Jack, I. & Shaw, A. T. Tumour heterogeneity and resistance to cancer therapies. Nat. Rev. Clin. Oncol. 15, 81\u201394 (2018).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"9760_CR5","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/j.cell.2017.01.018","volume":"168","author":"N McGranahan","year":"2017","unstructured":"McGranahan, N. & Swanton, C. Clonal heterogeneity and tumor evolution: past, present, and the future. Cell 168, 613\u2013628 (2017).","journal-title":"Cell"},{"key":"9760_CR6","doi-asserted-by":"publisher","first-page":"1847","DOI":"10.1158\/2159-8290.CD-21-0282","volume":"12","author":"DB Burkhardt","year":"2022","unstructured":"Burkhardt, D. B., San Juan, B. P., Lock, J. G., Krishnaswamy, S. & Chaffer, C. L. Mapping phenotypic plasticity upon the cancer cell state landscape using manifold learning. Cancer Discov. 12, 1847\u20131859 (2022).","journal-title":"Cancer Discov."},{"key":"9760_CR7","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1038\/s41568-019-0154-4","volume":"19","author":"I Arozarena","year":"2019","unstructured":"Arozarena, I. & Wellbrock, C. Phenotype plasticity as enabler of melanoma progression and therapy resistance. Nat. Rev. Cancer 19, 377\u2013391 (2019).","journal-title":"Nat. Rev. Cancer"},{"key":"9760_CR8","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","volume":"12","author":"D Hanahan","year":"2022","unstructured":"Hanahan, D. Hallmarks of cancer: new dimensions. Cancer Discov. 12, 31\u201346 (2022).","journal-title":"Cancer Discov."},{"key":"9760_CR9","doi-asserted-by":"crossref","unstructured":"Kavran, A. J. et al. Intermittent treatment of BRAFV600E melanoma cells delays resistance by adaptive resensitization to drug rechallenge. Proc. Natl. Acad. Sci. USA 119, e2113535119 (2022).","DOI":"10.1073\/pnas.2113535119"},{"key":"9760_CR10","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1038\/s41586-021-04206-7","volume":"601","author":"KA Fennell","year":"2022","unstructured":"Fennell, K. A. et al. Non-genetic determinants of malignant clonal fitness at single-cell resolution. Nature 601, 125\u2013131 (2022).","journal-title":"Nature"},{"key":"9760_CR11","doi-asserted-by":"publisher","first-page":"112252","DOI":"10.1016\/j.celrep.2023.112252","volume":"42","author":"J-Y Chen","year":"2023","unstructured":"Chen, J.-Y. et al. Multi-range ERK responses shape the proliferative trajectory of single cells following oncogene induction. Cell Rep. 42, 112252 (2023).","journal-title":"Cell Rep."},{"key":"9760_CR12","doi-asserted-by":"publisher","first-page":"031501","DOI":"10.1088\/1478-3975\/ac4ee2","volume":"19","author":"J Foo","year":"2022","unstructured":"Foo, J. et al. Roadmap on plasticity and epigenetics in cancer. Phys. Biol. 19, 031501 (2022).","journal-title":"Phys. Biol."},{"key":"9760_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15252\/msb.202210988","volume":"19","author":"F Fr\u00f6hlich","year":"2023","unstructured":"Fr\u00f6hlich, F., Gerosa, L., Muhlich, J. & Sorger, P. K. Mechanistic model of MAPK signaling reveals how allostery and rewiring contribute to drug resistance. Mol. Syst. Biol. 19, 1\u201326 (2023).","journal-title":"Mol. Syst. Biol."},{"key":"9760_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-02391-6","volume":"9","author":"M Schubert","year":"2018","unstructured":"Schubert, M. et al. Perturbation-response genes reveal signaling footprints in cancer gene expression. Nat. Commun. 9, 20 (2018).","journal-title":"Nat. Commun."},{"key":"9760_CR15","doi-asserted-by":"crossref","unstructured":"Easwaran, H., Tsai, H. C. & Baylin, S. B. Cancer epigenetics: tumor heterogeneity, plasticity of stem-like states, and drug resistance. Mol. Cell 54, 716\u2013727 (2014).","DOI":"10.1016\/j.molcel.2014.05.015"},{"key":"9760_CR16","doi-asserted-by":"crossref","unstructured":"Wellbrock, C. & Hurlstone, A. Braf as therapeutic target in melanoma. Biochem. Pharmacol. 80, 561\u2013567 (2010).","DOI":"10.1016\/j.bcp.2010.03.019"},{"key":"9760_CR17","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1016\/j.cels.2020.10.002","volume":"11","author":"L Gerosa","year":"2020","unstructured":"Gerosa, L. et al. Receptor-Driven ERK pulses reconfigure MAPK signaling and enable persistence of drug-adapted BRAF-mutant melanoma cells. Cell Syst. 11, 478\u2013494 (2020).","journal-title":"Cell Syst."},{"key":"9760_CR18","doi-asserted-by":"crossref","unstructured":"Chisholm, R. H. et al. Emergence of drug tolerance in cancer cell populations: an evolutionary outcome of selection, nongenetic instability, and stress-induced adaptation. Cancer Res. 75, 930\u2013939 (2015).","DOI":"10.1158\/0008-5472.CAN-14-2103"},{"key":"9760_CR19","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.jtbi.2015.08.031","volume":"386","author":"T Lorenzi","year":"2015","unstructured":"Lorenzi, T., Chisholm, R. H., Desvillettes, L. & Hughes, B. D. Dissecting the dynamics of epigenetic changes in phenotype-structured populations exposed to fluctuating environments. J. Theor. Biol. 386, 166\u2013176 (2015).","journal-title":"J. Theor. Biol."},{"key":"9760_CR20","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/S1470-2045(17)30171-7","volume":"18","author":"M Schreuer","year":"2017","unstructured":"Schreuer, M. et al. Combination of dabrafenib plus trametinib for BRAF and MEK inhibitor pretreated patients with advanced brafv600-mutant melanoma: an open-label, single arm, dual-centre, phase 2 clinical trial. Lancet Oncol. 18, 464\u2013472 (2017).","journal-title":"Lancet Oncol."},{"key":"9760_CR21","doi-asserted-by":"crossref","unstructured":"Reschke, R., Simon, J. C. & Ziemer, M. Rechallenge of targeted therapy in metastatic melanoma. J. Dtsch. Dermatol. Ges. 17, 483\u2013486 (2019).","DOI":"10.1111\/ddg.13766"},{"key":"9760_CR22","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/S0092-8674(00)81683-9","volume":"100","author":"D Hanahan","year":"2000","unstructured":"Hanahan, D. & Weinberg, R. A. The hallmarks of cancer. Cell 100, 57\u201370 (2000).","journal-title":"Cell"},{"key":"9760_CR23","doi-asserted-by":"publisher","first-page":"4487","DOI":"10.1158\/0008-5472.CAN-22-2217","volume":"82","author":"E Madan","year":"2022","unstructured":"Madan, E. et al. Cell competition in carcinogenesis. Cancer Res. 82, 4487\u20134496 (2022).","journal-title":"Cancer Res."},{"key":"9760_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.7554\/eLife.76284","volume":"11","author":"J Zhang","year":"2022","unstructured":"Zhang, J., Cunningham, J., Brown, J. & Gatenby, R. Evolution-based mathematical models significantly prolong response to abiraterone in metastatic castrate-resistant prostate cancer and identify strategies to further improve outcomes. Elife 11, 1\u2013105 (2022).","journal-title":"Elife"},{"key":"9760_CR25","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1158\/0008-5472.CAN-19-2669","volume":"80","author":"J West","year":"2020","unstructured":"West, J. et al. Towards multidrug adaptive therapy. Cancer Res. 80, 1578\u20131589 (2020).","journal-title":"Cancer Res."},{"key":"9760_CR26","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1038\/s43856-022-00110-x","volume":"2","author":"MAR Strobl","year":"2022","unstructured":"Strobl, M. A. R. et al. Spatial structure impacts adaptive therapy by shaping intra-tumoral competition. Commun. Med. 2, 46 (2022).","journal-title":"Commun. Med."},{"key":"9760_CR27","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1038\/s41559-021-01428-w","volume":"5","author":"Y Viossat","year":"2021","unstructured":"Viossat, Y. & Noble, R. A theoretical analysis of tumour containment. Nat. Ecol. Evol. 5, 826\u2013835 (2021).","journal-title":"Nat. Ecol. Evol."},{"key":"9760_CR28","doi-asserted-by":"publisher","first-page":"4894","DOI":"10.1158\/0008-5472.CAN-08-3658","volume":"69","author":"RA Gatenby","year":"2009","unstructured":"Gatenby, R. A., Silva, A. S., Gillies, R. J. & Frieden, B. R. Adaptive therapy. Cancer Res. 69, 4894\u20134903 (2009).","journal-title":"Cancer Res."},{"key":"9760_CR29","doi-asserted-by":"crossref","unstructured":"Gatenby, R. A. & Brown, J. S. Integrating evolutionary dynamics into cancer therapy. Nat. Rev. Clin. Oncol. 17, 675\u2013686 (2020).","DOI":"10.1038\/s41571-020-0411-1"},{"key":"9760_CR30","doi-asserted-by":"crossref","unstructured":"Bhat, G. R. et al. Cancer cell plasticity: from cellular, molecular, and genetic mechanisms to tumor heterogeneity and drug resistance. Cancer Metastasis Rev. 43, 197\u2013228 (2024).","DOI":"10.1007\/s10555-024-10172-z"},{"key":"9760_CR31","doi-asserted-by":"publisher","first-page":"e1013202","DOI":"10.1371\/journal.pcbi.1013202","volume":"21","author":"AP Browning","year":"2025","unstructured":"Browning, A. P. et al. Identifiability of heterogeneous phenotype adaptation from low-cell-count experiments and a stochastic model. PLoS Comput. Biol. 21, e1013202 (2025).","journal-title":"PLoS Comput. Biol."},{"key":"9760_CR32","doi-asserted-by":"crossref","unstructured":"Russo, M. et al. A modified fluctuation-test framework characterizes the population dynamics and mutation rate of colorectal cancer persister cells. Nat. Genet. 54, 976\u2013984 (2022).","DOI":"10.1038\/s41588-022-01105-z"},{"key":"9760_CR33","doi-asserted-by":"crossref","unstructured":"Gevertz, J. L., Greene, J. M., Prosperi, S., Comandante-Lou, N. & Sontag, E. D. Understanding therapeutic tolerance through a mathematical model of drug-induced resistance. NPJ Syst. Biol. Appl. 11, 30 (2024).","DOI":"10.1038\/s41540-025-00511-3"},{"key":"9760_CR34","doi-asserted-by":"crossref","unstructured":"Wu, C., Gunnarsson, E. B., Foo, J. & Leder, K. A statistical framework for detecting therapy-induced resistance from drug screens. NPJ Syst. Biol. Appl. 11, 88 (2024).","DOI":"10.1038\/s41540-025-00560-8"},{"key":"9760_CR35","doi-asserted-by":"crossref","unstructured":"Gupta, P. B. et al. Stochastic state transitions give rise to phenotypic equilibrium in populations of cancer cells. Cell 146 (2011).","DOI":"10.1016\/j.cell.2011.08.030"},{"key":"9760_CR36","doi-asserted-by":"crossref","unstructured":"Buder, T., Deutsch, A., Seifert, M. & Voss-B\u00f6hme, A. Celltrans: an R package to quantify stochastic cell state transitions. Bioinform. Biol. Insights 11, 1177932217712241 (2017).","DOI":"10.1177\/1177932217712241"},{"key":"9760_CR37","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1038\/nrc4029","volume":"15","author":"PM Altrock","year":"2015","unstructured":"Altrock, P. M., Liu, L. L. & Michor, F. The mathematics of cancer: integrating quantitative models. Nat. Rev. Cancer 15, 730\u2013745 (2015).","journal-title":"Nat. Rev. Cancer"},{"key":"9760_CR38","doi-asserted-by":"crossref","unstructured":"Rockne, R. C. et al. The 2019 mathematical oncology roadmap. Phys. Biol. 16, 041005 (2019).","DOI":"10.1088\/1478-3975\/ab1a09"},{"key":"9760_CR39","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1038\/s41416-021-01565-w","volume":"125","author":"SJ Hamis","year":"2021","unstructured":"Hamis, S. J. et al. Quantifying ERK activity in response to inhibition of the BRAFV600E-MEK-ERK cascade using mathematical modelling. Br. J. Cancer 125, 1552\u20131560 (2021).","journal-title":"Br. J. Cancer"},{"key":"9760_CR40","doi-asserted-by":"crossref","unstructured":"De Carli, A. et al. Simulating brafv600e-mek-erk signalling dynamics in response to vertical inhibition treatment strategies. npj Syst. Biol. and Appl. 10, 51 (2024).","DOI":"10.1038\/s41540-024-00379-9"},{"key":"9760_CR41","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.ebiom.2019.09.023","volume":"48","author":"I Smalley","year":"2019","unstructured":"Smalley, I. et al. Leveraging transcriptional dynamics to improve BRAF inhibitor responses in melanoma. EBioMedicine 48, 178\u2013190 (2019).","journal-title":"EBioMedicine"},{"key":"9760_CR42","doi-asserted-by":"publisher","first-page":"105499","DOI":"10.1016\/j.isci.2022.105499","volume":"25","author":"M Pillai","year":"2022","unstructured":"Pillai, M., Chen, Z., Jolly, M. K. & Li, C. Quantitative landscapes reveal trajectories of cell-state transitions associated with drug resistance in melanoma. iScience 25, 105499 (2022).","journal-title":"iScience"},{"key":"9760_CR43","doi-asserted-by":"crossref","unstructured":"Jain, P., Duddu, A. S. & Jolly, M. K. Stochastic population dynamics of cancer stemness and adaptive response to therapies. Essays Biochem. 66, 387\u2013398 (2022).","DOI":"10.1042\/EBC20220038"},{"key":"9760_CR44","doi-asserted-by":"crossref","unstructured":"Whiting, F. J., Househam, J., Baker, A. M., Sottoriva, A. & Graham, T. A. Phenotypic noise and plasticity in cancer evolution. Trends Cell Biol. 34, 451\u2013464 (2024).","DOI":"10.1016\/j.tcb.2023.10.002"},{"key":"9760_CR45","doi-asserted-by":"crossref","unstructured":"Clairambault, J. & Pouchol, C. A survey of adaptive cell population dynamics models of emergence of drug resistance in cancer, and open questions about evolution and cancer. Biomath 8, 23 (2019).","DOI":"10.11145\/j.biomath.2019.05.147"},{"key":"9760_CR46","doi-asserted-by":"crossref","unstructured":"Stace, R. E., Stiehl, T., Chaplain, M. A. J., Marciniak-Czochra, A. K. & Lorenzi, T. Discrete and continuum phenotype-structured models for the evolution of cancer cell populations under chemotherapy. Math. Model. Nat. Phenom. 15, 14 (2020).","DOI":"10.1051\/mmnp\/2019027"},{"key":"9760_CR47","doi-asserted-by":"crossref","unstructured":"Chisholm, R. H., Lorenzi, T. & Clairambault, J. Cell population heterogeneity and evolution towards drug resistance in cancer: Biological and mathematical assessment, theoretical treatment optimisation. Biochim. Biophys. Acta 1860, 2627\u20132645 (2016).","DOI":"10.1016\/j.bbagen.2016.06.009"},{"key":"9760_CR48","doi-asserted-by":"publisher","first-page":"e1009348","DOI":"10.1371\/journal.pcbi.1009348","volume":"17","author":"T Cassidy","year":"2021","unstructured":"Cassidy, T., Nichol, D., Robertson-Tessi, M., Craig, M. & Anderson, A. R. A. The role of memory in non-genetic inheritance and its impact on cancer treatment resistance. PLoS Comput. Biol. 17, e1009348 (2021).","journal-title":"PLoS Comput. Biol."},{"key":"9760_CR49","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1038\/s41573-019-0044-1","volume":"19","author":"S Boumahdi","year":"2020","unstructured":"Boumahdi, S. & de Sauvage, F. J. The great escape: tumour cell plasticity in resistance to targeted therapy. Nat. Rev. Drug Discov. 19, 39\u201356 (2020).","journal-title":"Nat. Rev. Drug Discov."},{"key":"9760_CR50","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1038\/s41568-022-00454-5","volume":"22","author":"M Labrie","year":"2022","unstructured":"Labrie, M., Brugge, J. S., Mills, G. B. & Zervantonakis, I. K. Therapy resistance: opportunities created by adaptive responses to targeted therapies in cancer. Nat. Rev. Cancer 22, 323\u2013339 (2022).","journal-title":"Nat. Rev. Cancer"},{"key":"9760_CR51","doi-asserted-by":"publisher","first-page":"2947","DOI":"10.1158\/0008-5472.CAN-19-0040","volume":"79","author":"MF Emmons","year":"2019","unstructured":"Emmons, M. F. et al. HDAC8 regulates a stress response pathway in melanoma to mediate escape from BRAF inhibitor therapy. Cancer Res. 79, 2947\u20132961 (2019).","journal-title":"Cancer Res."},{"key":"9760_CR52","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.1002\/ijc.31199","volume":"142","author":"SJ Gallagher","year":"2018","unstructured":"Gallagher, S. J. et al. HDAC inhibitors restore BRAF-inhibitor sensitivity by altering PI3K and survival signalling in a subset of melanoma. Int. J. Cancer 142, 1926\u20131937 (2018).","journal-title":"Int. J. Cancer"},{"key":"9760_CR53","doi-asserted-by":"publisher","first-page":"3157","DOI":"10.1158\/1078-0432.CCR-23-3171","volume":"30","author":"A Embaby","year":"2024","unstructured":"Embaby, A. et al. A proof-of-concept study of sequential treatment with the HDAC inhibitor vorinostat following BRAF and MEK inhibitors in BRAF V600 -mutated melanoma. Clin. Cancer Res. 30, 3157\u20133166 (2024).","journal-title":"Clin. Cancer Res."},{"key":"9760_CR54","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1158\/0008-5472.CAN-19-1941","volume":"80","author":"RA Gatenby","year":"2020","unstructured":"Gatenby, R. A., Artzy-Randrup, Y., Epstein, T., Reed, D. R. & Brown, J. S. Eradicating metastatic cancer and the eco-evolutionary dynamics of anthropocene extinctions. Cancer Res. 80, 613\u2013623 (2020).","journal-title":"Cancer Res."},{"key":"9760_CR55","doi-asserted-by":"publisher","first-page":"96","DOI":"10.3389\/fphys.2019.00096","volume":"10","author":"Z Wang","year":"2019","unstructured":"Wang, Z. & Deisboeck, T. S. Dynamic targeting in cancer treatment. Front. Physiol. 10, 96 (2019).","journal-title":"Front. Physiol."},{"key":"9760_CR56","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-23912-4","volume":"12","author":"KE Poels","year":"2021","unstructured":"Poels, K. E. et al. Identification of optimal dosing schedules of dacomitinib and osimertinib for a phase I\/II trial in advanced EFGR-mutant non-small cell lung cancer. Nat. Commun. 12, 3697 (2021).","journal-title":"Nat. Commun."},{"key":"9760_CR57","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-38239-5","volume":"14","author":"C Thirant","year":"2023","unstructured":"Thirant, C. et al. Reversible transitions between noradrenergic and mesenchymal tumor identities define cell plasticity in neuroblastoma. Nat. Commun. 14, 2575 (2023).","journal-title":"Nat. Commun."},{"key":"9760_CR58","doi-asserted-by":"publisher","first-page":"e14614","DOI":"10.1016\/j.heliyon.2023.e14614","volume":"9","author":"F Wang","year":"2023","unstructured":"Wang, F. & Zhu, L. Phenotypic plasticity promotes lymph nodes metastasis and drug resistance in lung squamous cell carcinomas. Heliyon 9, e14614 (2023).","journal-title":"Heliyon"},{"key":"9760_CR59","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1038\/s41392-023-01383-x","volume":"8","author":"Z-D Shi","year":"2023","unstructured":"Shi, Z.-D. et al. Tumor cell plasticity in targeted therapy-induced resistance: mechanisms and new strategies. Signal Transduct. Target. Ther. 8, 113 (2023).","journal-title":"Signal Transduct. Target. Ther."},{"key":"9760_CR60","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.cell.2010.02.027","volume":"141","author":"SV Sharma","year":"2010","unstructured":"Sharma, S. V. et al. A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell 141, 69\u201380 (2010).","journal-title":"Cell"},{"key":"9760_CR61","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms7139","volume":"6","author":"A Goldman","year":"2015","unstructured":"Goldman, A. et al. Temporally sequenced anticancer drugs overcome adaptive resistance by targeting a vulnerable chemotherapy-induced phenotypic transition. Nat. Commun. 6, 6139 (2015).","journal-title":"Nat. Commun."},{"key":"9760_CR62","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms10690","volume":"7","author":"M Ramirez","year":"2016","unstructured":"Ramirez, M. et al. Diverse drug-resistance mechanisms can emerge from drug-tolerant cancer persister cells. Nat. Commun. 7, 10690 (2016).","journal-title":"Nat. Commun."},{"key":"9760_CR63","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-16212-w","volume":"11","author":"R Vander Velde","year":"2020","unstructured":"Vander Velde, R. et al. Resistance to targeted therapies as a multifactorial, gradual adaptation to inhibitor specific selective pressures. Nat. Commun. 11, 2393 (2020).","journal-title":"Nat. Commun."}],"container-title":["Communications Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s42003-026-09760-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s42003-026-09760-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s42003-026-09760-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T16:04:07Z","timestamp":1773677047000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s42003-026-09760-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,26]]},"references-count":63,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["9760"],"URL":"https:\/\/doi.org\/10.1038\/s42003-026-09760-2","relation":{},"ISSN":["2399-3642"],"issn-type":[{"value":"2399-3642","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,26]]},"assertion":[{"value":"9 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"385"}}